Company news
Bio-thera Solutions, Ltd. Class A (SSE:688177) news
Bio-thera Solutions, Ltd. Class A news releases on 6ix. Latest, Aug 26, 2025: The European Commission (EC) Approves Bio-Thera Solutions' BAT2206 (USYMRO®…
Press releases — page 2
The European Commission (EC) Approves Bio-Thera Solutions' BAT2206 (USYMRO®, ustekinumab), a biosimilar referencing Stelara®
August 26, 2025
Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
August 22, 2025
Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital
August 20, 2025
Announcement on Result of Shareholding Reduction by Shareholder
August 19, 2025
Announcement on Return of Idle Raised Funds Temporarily Used to Supplement Current Capital
August 18, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT1308 Injection Combined with BAT4706 Injection and BAT8008 for Injection for Treatment of Advanced Solid Tumors
August 7, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (BAT5906)
August 1, 2025
Announcement on the Change of Office Address and Contact Information of Investors
July 31, 2025
Announcement on Voluntary Disclosure of Semi-annual Earnings Preannouncement for 2025
July 29, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT4406F Injection
July 21, 2025
Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi
July 17, 2025
Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi®
July 16, 2025
IDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial
July 2, 2025
Bio-Thera Solutions Announces First Patient Dosed in Phase 3 Clinical Trial for BAT8006, an Antibody Drug Conjugate Targeting Folate Receptor α for the Treatment of Platinum-Resistant Ovarian Cancer
June 25, 2025
Bio-Thera Solutions and SteinCares Expand Partnership to Commercialize Biosimilars for Treatment of Inflammatory Diseases Across Latin America
June 25, 2025
Announcement on Voluntary Disclosure of Signing Authorization License and Production, Supply and Commercialization Agreement with SteinCares for BAT2406 (Dupilumab) Injection
June 23, 2025
Bio-Thera Solutions Receives Positive CHMP Opinion for USYMRO®(ustekinumab), a Biosimilar Referencing Stelara®
June 20, 2025
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
May 27, 2025
Announcement on FDA Approval for BAT2206 (Ustekinumab) Injection in the United States
May 23, 2025
Announcement on Adjusting the Development Strategy of BAT3306 (Pembrolizumab)
May 22, 2025
Announcement on Completing the Term Change and Election of the Board of Directors and Appointment of Senior Management Members, Securities Affairs Representatives, and Head of Internal Audit
April 30, 2025
Report for Q1 2025
April 28, 2025
Announcement on Share Reduction Plan for Shareholders
April 23, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT7111 for Injection
April 21, 2025
Announcement on Election of Employee Representative Director for the Third Board of Directors
April 18, 2025
Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
April 14, 2025
Notice on Convening the 2024 Annual General Meeting
April 8, 2025
Announcement on the Latest Development of BAT1806 (Tocilizumab) Business
April 1, 2025
Announcement on Voluntary Disclosure of Progress of Down-payment Received for Signing Authorization License and Commercialization Agreement with Intas Pharmaceuticals Ltd. for BAT2506 (Golimumab) Injection
March 31, 2025
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia
March 27, 2025
Announcement on Resolution of the 18th Meeting of the 2nd Board of Supervisors
March 21, 2025
Announcement on Obtaining Acceptance of Application for Marketing Authorization of Golimumab Injection (BAT2506)
March 13, 2025
Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi (golimumab), in the United States of America
February 11, 2025
Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2506, a Proposed Biosimilar to Simponi, in the European Union
February 10, 2025
Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders
January 15, 2025
Bio-Thera Solutions Expands Partnership With SteinCares To Market Two Biosimilars In LATAM
December 30, 2024
Bio-Thera And Gedeon Richter Reach Exclusive Commercialization Agreement For Ustekinumab Biosimilar
November 4, 2024
Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, a Proposed Biosimilar of Keytruda
July 26, 2024
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
May 29, 2024
Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor
March 26, 2024
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar
June 16, 2023
Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting
April 17, 2023
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
March 13, 2023
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors
March 8, 2023
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors
March 6, 2023
China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra
January 17, 2023